🔗 Share this article

As the US proceeds with historic changes to its vaccine recommendations, an unexpected name has surfaced in a surprising turn: Dr. Tracy Beth Høeg, an American of Danish descent sports medicine doctor and epidemiologist who first made her name by questioning COVID-19 vaccines in the pandemic and has focused upon possible fatalities after COVID-19 vaccination in her brief tenure at the Food and Drug Administration.

Scheduled Overhauls to Childhood Vaccine Program

Agency leaders were set to announce major changes to the childhood vaccination calendar in December, bringing the US with the Danish vaccine program, it is understood – a substantial departure that would put the US at odds with a large portion of the world with little proof for public health gain. The planned update has been postponed until the new year.

Instead of Vinay Prasad, Høeg is listed to speak at the meeting. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the office this year.

A New Direction at the Regulatory Body

Høeg's temporary position could signify a closer partnership between the drug and biologics branches as Dr. Høeg and Prasad solidify control at the regulatory agency – and it points to a greater focus upon dismantling previously authorized vaccines at the FDA.

The new acting director has repeatedly called for ending some childhood shot schedules in the US in order to be more in line with the Danish model, a nation with comprehensive healthcare and a number of inhabitants roughly the population of Wisconsin’s.

In her initial statements, she has continued to focus on vaccines – typically the domain of Dr. Prasad, head of the FDA’s CBER – instead of pharmaceutical oversight.

Concerns Over Background

Dr. Høeg has no obvious background in medication creation, regulation or management, which has been typical for former leaders of the CBER. She has served at the FDA as a key advisor to the commissioner and CBER since earlier this year.

“She appears not to have the requisite experience” for overseeing the drug-regulation department, remarked a neurologist and psychiatrist. “She’s never run a randomized controlled trial. She has no expertise in managing a major agency. She is not an expert in drug approvals.”

Previous directors of the center would “understand regulatory frameworks and the underlying principles of medication creation”, commented Janet Woodcock. “Objectively, she doesn’t have the sort of resume that previous people who led CBER have had.”

CDER has an enormous portfolio at the FDA, she pointed out.

“Many people just focuses on the new drug program, but the off-patent medication office approves numerous off-brand pharmaceuticals. There is also a biosimilars division, non-prescription drug unit and other areas, and each of these need to be managed,” Dr. Woodcock noted. “The area you neglect, that is the part that I always told people is going to bite you.”

Furthermore, a significant management component to the role, which supervises in excess of 5,000 personnel. “It is a enormous leadership role, if you perform it correctly,” Woodcock added.

Official Statement and Contentious Initiatives

When asked about concerns about Dr. Høeg's fitness for the role and whether this selection represents greater collaboration among agency officials on vaccines, a representative stated that the “concerns rely on inaccurate assumptions”.

“This background is consistent with the responsibilities of her role,” the official explained, pointing to the months Dr. Høeg spent guiding the agency head on “drug safety and approval science, including computerized risk analysis and shot safety tracking”.

In her interim role, Høeg assumes responsibility for the agency head's recently launched priority voucher program, a controversial expedited therapy clearance system that apparently worried her preceding directors. “By what process are these therapies being picked for this voucher program? Who is making the calls?” Howard said. “There is a lot of lack of transparency occurring at the agency right now.”

In general, he said, “the agency appears to be shifting towards more relaxed oversight of pharmaceuticals, aside from shots.”

Established Track Record on Vaccines

Regarding vaccines, Dr. Høeg has a clearer, if problematic, past, critics have noted. She authored a study using unverified volunteer-provided data to assess the incidence of myocarditis after Covid immunization. She advised the state of Florida chief medical officer Joseph Ladapo, who was said to have modified findings to suggest Covid vaccinations are pose a greater threat than they are.

Part of her “wish list” for the new federal leadership featured revising regulations for recently developed shots and discontinuing “non-essential” immunizations, she said following the vote on a podcast. At the agency, Høeg has allegedly suggested excluding adolescent males from getting COVID-19 vaccines.

“She is an thorough true believer who begins with her conclusions and works backwards to fit the evidence in a highly deceptive, untruthful manner,” Howard argued.

Gaining Influence and a “Push for Payback”

Dr. Høeg aligned with other dissenters, {like|